RRAS2

Across TCGA pan-cancer cohorts, RRAS2 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of RRAS2’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where RRAS2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types RRAS2 is over-expressed in tumor, although a few such as COAD and CCRCC show the opposite, repressed pattern.

COAD, CCRCC, and LUAD are the cancer types where RRAS2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RRAS2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Male	III,IV	−1.106	<.001	12	view →
CCRCC	Female	III,IV	−0.935	<.001	12	view →
LUAD	Male	III,IV	−0.755	<.001	8	view →
LSCC	Female	All	−0.599	<.001	8	view →
HNSC	Male	III,IV	+0.352	<.001	8	view →
PDAC	All	All	−0.277	.002	4	view →
OV	All	All	−0.462	.035	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

RRAS2–COAD

Open the COAD breakdown →